Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS study
Autor(a) principal: | |
---|---|
Data de Publicação: | 2006 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://dx.doi.org/10.1590/S0004-27302006000200023 http://repositorio.unifesp.br/handle/11600/3047 |
Resumo: | Weight loss improves metabolic abnormalities and reduces cardiovascular risk in obese hypertensive patients. To evaluate the impact of a sustained weight loss on coronary risk, 181 hypertensive patients with metabolic syndrome underwent to orlistat therapy, 120 mg, t.i.d., plus diet for 36 weeks. During therapy, Framingham risk scores (FRS) were calculated for determination of coronary heart disease risk in ten years. Body mass index decreased from 35.0 ± 4.2 to 32.6 ± 4.5 kg/m² (p< 0.0001) and waist circumference from 108.1 ± 10.1 to 100.5 ± 11.1 cm (p< 0.0001), at the end of the study period (week 36). Systolic and diastolic blood pressure showed reductions after the two first weeks, which were maintained up to the end of the study. A clear shift to the left in FRS distribution curve occurred at the end of the study, compared to baseline, indicating a reduction in coronary risk. Over all patients at risk, 49.2% moved to a lower risk category. A weight loss > 5% occurred in 64.6% of all patients, associated with improvement in glucose metabolism. Among those with abnormal glucose metabolism, 38 out 53 patients (71.7%) improved their glucose tolerance (p< 0.0005). In conclusion, long-term orlistat therapy helps to reduce and maintain a lower body weight, decreasing risk of coronary disease and improving glucose metabolism, thus protecting against type 2 diabetes. |
id |
UFSP_f96504a25fb9f717a8803a6310fd9580 |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br/:11600/3047 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS studyAvaliação do risco cardiovascular em pacientes obesos hipertensos com síndrome metabólica: estudo ARCOSCentral obesityOrlistatWeight reductionCardiovascular riskFramingham risk scoreObesidade centralOrlistatRedução de pesoRisco cardiovascularScore de risco de FraminghamWeight loss improves metabolic abnormalities and reduces cardiovascular risk in obese hypertensive patients. To evaluate the impact of a sustained weight loss on coronary risk, 181 hypertensive patients with metabolic syndrome underwent to orlistat therapy, 120 mg, t.i.d., plus diet for 36 weeks. During therapy, Framingham risk scores (FRS) were calculated for determination of coronary heart disease risk in ten years. Body mass index decreased from 35.0 ± 4.2 to 32.6 ± 4.5 kg/m² (p< 0.0001) and waist circumference from 108.1 ± 10.1 to 100.5 ± 11.1 cm (p< 0.0001), at the end of the study period (week 36). Systolic and diastolic blood pressure showed reductions after the two first weeks, which were maintained up to the end of the study. A clear shift to the left in FRS distribution curve occurred at the end of the study, compared to baseline, indicating a reduction in coronary risk. Over all patients at risk, 49.2% moved to a lower risk category. A weight loss > 5% occurred in 64.6% of all patients, associated with improvement in glucose metabolism. Among those with abnormal glucose metabolism, 38 out 53 patients (71.7%) improved their glucose tolerance (p< 0.0005). In conclusion, long-term orlistat therapy helps to reduce and maintain a lower body weight, decreasing risk of coronary disease and improving glucose metabolism, thus protecting against type 2 diabetes.A perda de peso melhora as anormalidades metabólicas e reduz o risco cardiovascular em pacientes obesos hipertensos. Com o objetivo de avaliar o impacto da perda de peso mantida sobre o risco coronariano, submetemos 181 pacientes hipertensos com síndrome metabólica à terapia com orlistat, 120 mg, três vezes ao dia, mais dieta, por um período de 36 semanas. Durante a terapia, foram calculados os scores de risco de Framingham (FRS) para a determinação do risco de doença cardíaca coronariana em dez anos. Ao final do período de estudo (semana 36), o índice de massa corpóreo diminuiu de 35,0 ± 4,2 para 32,6 ± 4,5 kg/m² (p< 0,0001) e a circunferência da cintura de 108,1 ± 10,1 para 100,5 ± 11,1 cm (p< 0,0001). As pressões sistólica e diastólica mostraram reduções após as primeiras duas semanas, que se mantiveram até o final do estudo. Um deslocamento evidente para a esquerda na curva de distribuição do FRS ocorreu no final do estudo, em comparação com os valores basais, indicando redução no risco coronariano. Do total de pacientes em risco, 49,2% passou para uma categoria de risco menor. Ocorreu perda de peso > 5% em 64,6% de todos os pacientes, associada com melhora no metabolismo da glicose. Entre os 53 pacientes com metabolismo de glicose anormal, 38 (71,7%) melhoraram sua tolerância à glicose (p< 0,0005). Em conclusão, terapia de longa duração com orlistat auxilia a reduzir e manter mais baixo o peso corpóreo, reduzindo o risco de doença coronária e melhorando o metabolismo da glicose e protegendo, dessa maneira, contra o diabetes tipo 2.Federal University of São Paulo Divisions of EndocrinologyFederal University of São Paulo Division of NephrologyInstituto Dante Pazzaneze de Cardiologia Service of CardiologyRoche LaboratoriesUNIFESP, Divisions of EndocrinologyUNIFESP, Division of NephrologySciELOSociedade Brasileira de Endocrinologia e MetabologiaUniversidade Federal de São Paulo (UNIFESP)Instituto Dante Pazzaneze de Cardiologia Service of CardiologyRoche LaboratoriesZanella, Maria Teresa [UNIFESP]Uehara, Marcelo Hiroshi [UNIFESP]Ribeiro, Artur Beltrame [UNIFESP]Bertolami, MarceloFalsetti, Ana ClaudiaYunes, Mirela A.2015-06-14T13:32:05Z2015-06-14T13:32:05Z2006-04-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion368-376application/pdfhttp://dx.doi.org/10.1590/S0004-27302006000200023Arquivos Brasileiros de Endocrinologia & Metabologia. Sociedade Brasileira de Endocrinologia e Metabologia, v. 50, n. 2, p. 368-376, 2006.10.1590/S0004-27302006000200023S0004-27302006000200023.pdf0004-2730S0004-27302006000200023http://repositorio.unifesp.br/handle/11600/3047engArquivos Brasileiros de Endocrinologia & Metabologiainfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-08-04T21:22:10Zoai:repositorio.unifesp.br/:11600/3047Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-08-04T21:22:10Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.none.fl_str_mv |
Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS study Avaliação do risco cardiovascular em pacientes obesos hipertensos com síndrome metabólica: estudo ARCOS |
title |
Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS study |
spellingShingle |
Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS study Zanella, Maria Teresa [UNIFESP] Central obesity Orlistat Weight reduction Cardiovascular risk Framingham risk score Obesidade central Orlistat Redução de peso Risco cardiovascular Score de risco de Framingham |
title_short |
Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS study |
title_full |
Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS study |
title_fullStr |
Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS study |
title_full_unstemmed |
Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS study |
title_sort |
Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS study |
author |
Zanella, Maria Teresa [UNIFESP] |
author_facet |
Zanella, Maria Teresa [UNIFESP] Uehara, Marcelo Hiroshi [UNIFESP] Ribeiro, Artur Beltrame [UNIFESP] Bertolami, Marcelo Falsetti, Ana Claudia Yunes, Mirela A. |
author_role |
author |
author2 |
Uehara, Marcelo Hiroshi [UNIFESP] Ribeiro, Artur Beltrame [UNIFESP] Bertolami, Marcelo Falsetti, Ana Claudia Yunes, Mirela A. |
author2_role |
author author author author author |
dc.contributor.none.fl_str_mv |
Universidade Federal de São Paulo (UNIFESP) Instituto Dante Pazzaneze de Cardiologia Service of Cardiology Roche Laboratories |
dc.contributor.author.fl_str_mv |
Zanella, Maria Teresa [UNIFESP] Uehara, Marcelo Hiroshi [UNIFESP] Ribeiro, Artur Beltrame [UNIFESP] Bertolami, Marcelo Falsetti, Ana Claudia Yunes, Mirela A. |
dc.subject.por.fl_str_mv |
Central obesity Orlistat Weight reduction Cardiovascular risk Framingham risk score Obesidade central Orlistat Redução de peso Risco cardiovascular Score de risco de Framingham |
topic |
Central obesity Orlistat Weight reduction Cardiovascular risk Framingham risk score Obesidade central Orlistat Redução de peso Risco cardiovascular Score de risco de Framingham |
description |
Weight loss improves metabolic abnormalities and reduces cardiovascular risk in obese hypertensive patients. To evaluate the impact of a sustained weight loss on coronary risk, 181 hypertensive patients with metabolic syndrome underwent to orlistat therapy, 120 mg, t.i.d., plus diet for 36 weeks. During therapy, Framingham risk scores (FRS) were calculated for determination of coronary heart disease risk in ten years. Body mass index decreased from 35.0 ± 4.2 to 32.6 ± 4.5 kg/m² (p< 0.0001) and waist circumference from 108.1 ± 10.1 to 100.5 ± 11.1 cm (p< 0.0001), at the end of the study period (week 36). Systolic and diastolic blood pressure showed reductions after the two first weeks, which were maintained up to the end of the study. A clear shift to the left in FRS distribution curve occurred at the end of the study, compared to baseline, indicating a reduction in coronary risk. Over all patients at risk, 49.2% moved to a lower risk category. A weight loss > 5% occurred in 64.6% of all patients, associated with improvement in glucose metabolism. Among those with abnormal glucose metabolism, 38 out 53 patients (71.7%) improved their glucose tolerance (p< 0.0005). In conclusion, long-term orlistat therapy helps to reduce and maintain a lower body weight, decreasing risk of coronary disease and improving glucose metabolism, thus protecting against type 2 diabetes. |
publishDate |
2006 |
dc.date.none.fl_str_mv |
2006-04-01 2015-06-14T13:32:05Z 2015-06-14T13:32:05Z |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1590/S0004-27302006000200023 Arquivos Brasileiros de Endocrinologia & Metabologia. Sociedade Brasileira de Endocrinologia e Metabologia, v. 50, n. 2, p. 368-376, 2006. 10.1590/S0004-27302006000200023 S0004-27302006000200023.pdf 0004-2730 S0004-27302006000200023 http://repositorio.unifesp.br/handle/11600/3047 |
url |
http://dx.doi.org/10.1590/S0004-27302006000200023 http://repositorio.unifesp.br/handle/11600/3047 |
identifier_str_mv |
Arquivos Brasileiros de Endocrinologia & Metabologia. Sociedade Brasileira de Endocrinologia e Metabologia, v. 50, n. 2, p. 368-376, 2006. 10.1590/S0004-27302006000200023 S0004-27302006000200023.pdf 0004-2730 S0004-27302006000200023 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Arquivos Brasileiros de Endocrinologia & Metabologia |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
368-376 application/pdf |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Endocrinologia e Metabologia |
publisher.none.fl_str_mv |
Sociedade Brasileira de Endocrinologia e Metabologia |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
biblioteca.csp@unifesp.br |
_version_ |
1814268286579245056 |